Overview

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria
Phase:
Phase 2
Details
Lead Sponsor:
Escient Pharmaceuticals, Inc